The levonorgestrel-releasing intrauterine system 52 mg as a contraceptive versus a therapeutic: essential differences and perspectives

References

• Allen E, Doisy EA. An ovarian hormone: preliminary report on its localization, extraction and partial purification and action in test animal. JAMA. 1923;81(10):819–821.
   Google Scholar
• Corner GW, Allen WM. Physiology of the corpus luteum, II: production of a special uterine reaction (progestational proliferation) by extracts of the corpus luteum. Am J Physiol. 1929;88:326–399.
   Google Scholar
• Djerassi C, Miramontes L, Rosenkranz G, et al. Steroids. LIV.1 synthesis of 19-Nov-17α-ethynyltestosterone and 19-nor-17α-methyltestosterone. J Am Chem Soc. 1954;76:4092–4094.
   Web of Science ®Google Scholar
• Zanartu J, Pupkin M, Rosenberg D, et al. Effect of oral continuous progestogen therapy in microdosage on human ovary and sperm transport. Br Med J. 1968;2:266–269.
   PubMedGoogle Scholar
• Scommegna A, Pandya GN, Christ M, et al. Intauterine administration of progesterone by a slow releasing device. Fertil Steril. 1970;21:201–210.
   PubMed Web of Science ®Google Scholar
• Cohen MR, Pandya G, Scommegna A. The effects of an intracervical steroid- releasing device on the cervical mucus. Fertil Steril. 1970;21(10):715–723.
   PubMed Web of Science ®Google Scholar
• Pharriss BB, Erickson R, Bashaw J, et al. Progestasert: a uterine therapeutic system for long-term contraception: i. Philosphy and clinical efficacy. Fertil Steril. 1974;25:915–921.
   PubMed Web of Science ®Google Scholar
• Newton J, Szontagh F, Rowe P. A collaborative study of the progesterone intrauterine device (progestasert). Contraception. 1979;19:575–589.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Johansson EDB, Luukkainen T. A d-norgestrel-releasing IUD. Contraception. 1976;13:503–514.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T. Improvement of a d-norgestrel-releasing IUD. Contraception. 1977;15:295–306.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steri. 1978;29:397–401.
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5:235–241.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982;17(6):529–536.
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Luukkainen T. Five years experience with a small intracervical/intrauterine levonorgestrel intrauterine device. Contraception. 2005;72(5):342–345.
   PubMed Web of Science ®Google Scholar
• Moraes LG, Marchi NM, Pitoli AC. Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different time of use. Eur J Contracept Reprod Healthcare. 2016;4:318–322.
   Google Scholar
• Creinin MD, Jansen R, Starr RM, et al. Levonorgestrel release rates over 5 years with the Lilletta© 52-mg inttrtauterine system. Contraception. 2016;94:353–356.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schreiber CA, Turok DK, et al. Levonorgestrel 52 mg intrauterine system: efficacy and safety through 8 years of use. AJOG. 2022;1:e7.
   Google Scholar
• Goldstuck ND. Clarification of the role of Jaydess (Skylar) LNG-IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. Ex Rev Med Devices. 2017;14:593–599.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Andrade A, Goldstuck ND. Femilis© 60 levonorgestrel-releasing intrauterine system-a review of 10 years of clinical experience. Clin Med Insights. 2016;10:19–27.
   Google Scholar
• Haukkama M, Allonen H, Heikkila M, et al. Long-term clinical experience with levonorgestrel-releasing IUD. In: Zatuchni GI, Goldsmith A, Sciarra JJ, editors. Intrauterine contraception: advances and future prospects. Philadelphia, PA: Harper and Row; 1985. p. 232–237.
   Google Scholar
• Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day device. Contraception. 1987;35:245–255.
   PubMed Web of Science ®Google Scholar
• Sivin I, El Magoub S, McCarthy T, et al. Long-term contraception with the Levonorgestrel 20 mcg/day (LNg 20) and the Copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990;42:361–378.
   PubMed Web of Science ®Google Scholar
• Sivin I, Stern J, Couthinho E, et al. Prolonged intrauterine contraception: a seven year randomized study of the levonorgestrel 20mcg/day (LNg 20) and the copper T380 AG IUDs. Contraception. 1991;44:473–480.
   PubMed Web of Science ®Google Scholar
• Rowe P, Farley T, Peregoudov P, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel medicated intrauterine device: a 7-year randomized comparative study with the TCu 380A. Contraception. 2016;93:498–506.
   PubMed Web of Science ®Google Scholar
• Goldthwaite LM, Creinin MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. Contraception. 2019;100:128–131.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65(2):129–132.
   PubMed Web of Science ®Google Scholar
• Turok DK, Gero A, Simmons RG, et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med. 2021;384(4):335–344.
   PubMed Web of Science ®Google Scholar
• Scholten PC, Christiaens GC, Haspels AA. 1989. Treatment of menorrhagia by intrauterine administration of levonorgestrel. In: Scholten, PE editor. The Levonorgestrel IUD: clinical performance and impact on menstruation. Thesis. Utrecht, The Netherlands: The University Hospital.
   Google Scholar
• Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception. 1995;52(5):269–276.
   PubMed Web of Science ®Google Scholar
• Pakarinen P, Luukkainen T. Treatment of menorrhagia with an LNG-IUS. Contraception. 2007;75:S118–S122.
   PubMed Web of Science ®Google Scholar
• Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Obst Gynecol. 2011;113:3–13.
   PubMed Web of Science ®Google Scholar
• Chowdary P, Maher P, Newman M, et al. The role of the Mirena intrauterine device in the management of endometrial polyps: a pilot study. J Min Inv Gynec. 2019;26:1297–1302.
   PubMed Web of Science ®Google Scholar
• Sletten ET, Arnes M, Vereide AB, et al. Intrauterine progestin therapy as a new approach to premalignant polyps. Anticancer Res. 2019;39:4897–4903.
   PubMed Web of Science ®Google Scholar
• Peng F-S, Wu M-Y, Yang J-H, et al. Insertion of the Mirena intrauterine system for treatment of adenomyosis associated menorrhagia: a novel method. Taiwan J Obstet Gynecol. 2010;49:160–164.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Shacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel “frameless” intrauterine levonorgestrel-releasing drug delivery system: a pilot study. EJOG. 2002;102:74–79.
   Google Scholar
• Kaunitz AM. Progestin- releasing intrauterine systems and leiomyoma. Contraception. 2007;75:S130–S133.
   PubMed Web of Science ®Google Scholar
• Dore M, Filoche S, Danielson K, et al. Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: can biomarkers predict response. Gynecol Oncol Reports. 2021;36:100732.
   PubMed Web of Science ®Google Scholar
• Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders:long -term follow-up. Contraception. 2011;83:242–247.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamaslita MA, et al. Treatment of menorrhagia associated with anticoagulation:efficacy and safety of the levonorgestrel intrauterine device. Lupus. 2006;15:877–880.
   PubMed Web of Science ®Google Scholar
• Vasudeva S, Malhotra G, Gulati SK, et al. Mirena and NuvaRing in management in dysfunctional uterine bleeding. Int J Contemp Med Res. 2018;5:254–7379.
   Google Scholar
• Akram Z, Mahjabeen I, Irshad F, et al. Expression deregulation of matrix metalloproteinases and vasoconstriction related genes in Pakistani females with abnormal uterine bleeding. BMC Women’s Health. 2022;22:543.
   PubMed Web of Science ®Google Scholar
• El-Nory MA, El-Habbaa GI, Rageh GI. Levonorgestrel-releasing intrauterine device for management of tamoxifen-induced menorrhagia in breast cancer patients. J Cancer Res Exp Oncol. 2014;6:6–12.
   Google Scholar
• Wildemeersch D, Shacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system:a pilot study. Eur J Contracept Reprod Health Care. 2001;6:192–198.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Jadi S, Pett A, et al. Management of primary dysmenorrhea in young women with frameless LNG-IUS. Open Access J Contracept. 2014;5:23–28.
   Google Scholar
• Carvalho N, Margatho D, Cursino K, et al. Control of endometriosis-associated pain with etonogestrel releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018;6:1129–1136.
   Google Scholar
• Margatho D, Carvalho NM, Bahamondes L. Endometriosis-associated pain scores and biomarkers in users of the etonogestrel-releasing subdermal implant or the 52-mglevonorgestrel-releasingintrauterine system for up to 24 months. Eur J Contracept Reprod Health Care. 2020;5:133–140.
   Google Scholar
• Varila E, Wahlstrom T, Rauramo I. A 5 year follow up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril. 2001;76(5):969–973.
   PubMed Web of Science ®Google Scholar
• Wildemeersch D, Shacht E. Endometrial suppression with a new ‘frameless’ levonorgestrel intrauterine system in perimenopausal and postmenopausal women: a pilot study. Maturitas. 2000;36:63–68.
   PubMed Web of Science ®Google Scholar
• Sletten ET, Arnes M, Vereide AB, et al. Low dose LNG-IUS as therapy for endometrial hyperplasia: a prospective cohort pilot study. Anticancer Res. 2018;38:2883–2889.
   PubMed Web of Science ®Google Scholar
• Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care. 2016;21:93–105.
   PubMed Web of Science ®Google Scholar
• Goldstuck ND. Modern menstruation: is it abnormal and unhealthy? Medical Hypoth. 2020;144:10995.
   Web of Science ®Google Scholar
• Guttinger A, Critchley HOD. Endometrial affects of intrauterine levonorgestrel. Contraception. 2007;75:S93–S98.
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Bahamondes MV, Shulman LP. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum Reprod Update. 2015;21:640–651.
   PubMed Web of Science ®Google Scholar
• Huxley A. Brave new world. Lonodon, United Kingdom: Chatto & Windus; 1932.
   Google Scholar
• Lyytinen HK, Dyba T, Ylikorkala O, et al. A case control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126:483–489.
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grenman S, et al. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124:292–299.
   PubMed Web of Science ®Google Scholar
• Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2020;99:970–982.
   PubMed Web of Science ®Google Scholar
• Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–2239.
   PubMed Web of Science ®Google Scholar
• Fels LM, Costescu D, Vieira CS, et al. The effect of a combined indomethacin and levonorgestrel-releasing intrauterine system on short-term post-placement bleeding profile: a randomized proof-of-concept trial. Am J Obstet Gynecol. 2022;228(3):322.e1–322.e15.
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Laateenmaki, P, Toivonen . Levonorgestrel-intrauterine device. Ann Med. 1990;22:85–90.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Kubba A, Caetano C, et al. Thirty years of Mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100:614–618.
   PubMed Web of Science ®Google Scholar